Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Hyperplasia 1Fibrous Dysplasia, Polyostotic 1Adenoma 1Acromegaly 1

Interventions

Cyclophosphamide 388Specimen Handling 377Magnetic Resonance Spectroscopy 328Radiotherapy 306Biopsy 273Cisplatin 258Carboplatin 255Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 183Bevacizumab 181Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 141Taxes 127Docetaxel 122Chemotherapy, Adjuvant 114Oxaliplatin 113fludarabine phosphate 111Methotrexate 108Rituximab 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × pegvisomant × Clear all
NCT00017927 2008-03-04

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
10 enrolled

Acromegaly, Adenoma, Fibrous Dysplasia, Polyostotic, Hyperplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡